Difficulty: Medium
Average Score: 63%
Practice
What is the first-line treatment for a neonate with respiratory distress syndrome (RDS)?
Correct answer
B
Rationale
In the management of neonates with respiratory distress syndrome (RDS), surfactant therapy is considered the first-line treatment. Surfactant is crucial for reducing surface tension in the alveoli, preventing their collapse, and improving lung compliance. Administering exogenous surfactant early in neonates with RDS has been shown to significantly improve outcomes by reducing the need for mechanical ventilation, decreasing the risk of complications such as bronchopulmonary dysplasia, and lowering mortality rates.
The other options presented are not the first-line treatment for RDS in neonates. Inhaled nitric oxide is used in conditions like persistent pulmonary hypertension of the newborn, not RDS. Mechanical ventilation and positive pressure ventilation are supportive measures that may be needed if the neonate's respiratory distress worsens or if surfactant therapy alone is insufficient. However, these are not the initial preferred treatments due to the potential risks associated with mechanical ventilation in neonates, such as barotrauma and volutrauma.
From an educational perspective, understanding the rationale behind selecting surfactant therapy as the first-line treatment for neonatal RDS is essential for nurses caring for neonates. It underscores the importance of timely intervention to improve oxygenation and decrease the risk of complications. Educators should emphasize the evidence-based approach to managing RDS and the critical role surfactant plays in enhancing neonatal respiratory function and outcomes. This knowledge equips nurses with the necessary skills to provide safe and effective care to neonates with respiratory distress.
The other options presented are not the first-line treatment for RDS in neonates. Inhaled nitric oxide is used in conditions like persistent pulmonary hypertension of the newborn, not RDS. Mechanical ventilation and positive pressure ventilation are supportive measures that may be needed if the neonate's respiratory distress worsens or if surfactant therapy alone is insufficient. However, these are not the initial preferred treatments due to the potential risks associated with mechanical ventilation in neonates, such as barotrauma and volutrauma.
From an educational perspective, understanding the rationale behind selecting surfactant therapy as the first-line treatment for neonatal RDS is essential for nurses caring for neonates. It underscores the importance of timely intervention to improve oxygenation and decrease the risk of complications. Educators should emphasize the evidence-based approach to managing RDS and the critical role surfactant plays in enhancing neonatal respiratory function and outcomes. This knowledge equips nurses with the necessary skills to provide safe and effective care to neonates with respiratory distress.